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Abstract
The protozoan hemoflagellate Trypanosoma cruzi (T. cruzi) is the etiologic agent of the 
zoonotic Chagas’ disease that affects approximately six to seven million people in 
Central and South America, causing dilated cardiomyopathy and megavisceral disease. 
Although Chagas’ disease is the leading cause of heart failure in Latin America among 
people living in poverty and places an immense socioeconomic burden on society, it is 
still currently classified as a neglected tropical disease (NTD). The disease is typically 
transmitted by reduviid bugs or orally by contaminated food, while the transmission 
of parasitic organisms by other routes such as blood transfusion, organ transplanta-
tion, and transplacental infection is relatively rare. Given the wide cellular tropism 
infecting virtually all nucleated cells, the protozoan is able to persist asymptomatically 
for decades until ultimately causing organ-specific symptoms of chronic Chagas’ dis-
ease such as chronic heart failure. The acute phase of the disease triggers an immune 
response that often does not restrict the dissemination of the parasite and may cause 
skin lesions, fever, enlarged lymph nodes, pallor, swelling, and abdominal and chest 
pain. Despite recent advances in our knowledge about the pathogenesis of this disease, 
the complex host-parasite interactions are not completely understood and, in particular, 
the persistence of parasites in host cells for such a long time remains largely undefined. 
In this book chapter, we focus on the pathophysiology of American trypanosomiasis and 
emphasize the role of host-specific transcription factors executing antiparasitic immune 
reactions.
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1. Introduction
The pathogenic protozoan Trypanosoma cruzi (T. cruzi) is the causative agent of Chagas’ dis-
ease, and more than 150 species of mammals are affected by this unicellular parasite, including 
humans. The parasite was discovered in 1909 by the Brazilian physician Carlos Chagas, while 
dissecting assassin bugs (Reduviidae) from the subfamily Triatominae that act as vectors and 
hosts for the parasite, and was later named after Chagas’ scientific mentor Oswaldo Cruz [1].
Chagas’ disease, also termed American trypanosomiasis, causes the third largest disease bur-
den of the tropics after malaria and schistosomiasis [2] and is responsible for higher morbidity 
and mortality than any other parasitic infection in America [3]. According to surveys of the 
World Health Organization (WHO) from 2014, six to seven million people worldwide are 
estimated to be infected with T. cruzi, while around 14,000 patients die annually as a result of 
the parasitosis. An overview of the geographic distribution of Chagas’ disease is presented 
in Figure 1.
The link between poverty and dissemination of Chagas’ disease is striking, as it particularly 
affects people living in simple huts made of mud and wood with roofs of straw or palm 
leaves in rural areas of Latin America, where the predatory bugs have easy access. In the most 
important endemic areas, vectors include Panstrongylus megistus, Triatoma infestans, T. dimidi-
ata, T. pallidipennis, and Rhodnius prolixus [4] (Figure 2). Non-vectorial transmission, such as 
the ingestion of T. cruzi-contaminated food and congenital transmission from the mother to 
the fetus [5] as well as blood transfusion and organ transplantation, increase the number of 
people at risk, estimated at 100 million worldwide. Owing to international migration, isolated 
cases of Chagas’ disease in nonendemic countries are increasingly being recognized.
Figure 1. Geographical distribution of Chagas’ disease. Dark blue indicates endemic countries and light blue nonendemic 
countries.
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2. Biology and life cycle of T. cruzi
Assassin bugs infected with T. cruzi preferably sting sleeping victims and usually suck their 
blood unnoticed. After the blood meal, the pressure in the bug’s gastrointestinal tract increases 
and the insect defecates on the skin near the wound. This behavior of Triatominae is crucial for 
their ability to act as a vector for T. cruzi, since infective stages of T. cruzi reach the stab wound 
only when the bugs defecate during food intake. The assassin bug transmits the parasites to 
the definitive host, by spreading excrement on the wound while escaping. When the pathogen-
containing feces are rubbed into the fresh puncture wound by the victim or when the pathogen 
penetrates into uninjured mucosa, especially those of the eye, highly infectious and very motile 
metacyclic trypomastigotes of T. cruzi are transmitted into the blood flow of the host [6, 7] 
(Figure 3). The trypomastigotes are then disseminated successively into the organism of the 
host, and preferably infect cells of the reticuloendothelial and mononuclear phagocytic system 
[8]. A parasitophorous vacuole is formed only briefly during the life cycle of T. cruzi, while 
the intracellular parasites multiply in the cytoplasm of the host cell by binary division [9, 10].
T. cruzi can infect any nucleated cell but predominantly replicates in cardiac muscle cells as 
well as in cells of the nervous system, gonads, intestinal mucosa, and placenta [11]. After pen-
etration into the cytoplasm of the host cell, the morphology of the metacyclic trypomastigotes 
Figure 2. Meccus pallidipennis (syn. Triatoma pallidipennis, Hemiptera: Reduviidae) from the subfamily Triatominae as a 
vector for T. cruzi.
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changes to intracellular amastigotes with diameters of 3–5 µm, when they lose their undulat-
ing membrane which is a characteristic feature of mobile trypomastigotes [9, 12] (Figure 4). 
Intracellular amastigotes undergo several rounds of division and are then transformed into 
trypomastigotes, approximately 20-µm long, which leave the host cell and spread further into 
the organism to infect new host cells [13]. Unlike the African sleeping sickness caused by T. 
brucei, intracellular replication of T. cruzi in host cells is mandatory, since the pathogenic agent 
of American trypanosomiasis is not able to divide in the blood. For this reason, the intracel-
lular amastigote form of T. cruzi is always present and can be histopathologically detected in 
tissue samples from spleen, liver, brain, and heart muscle. The life cycle of T. cruzi continues 
when the bug takes a blood meal from an infected host, and the parasites transform in the 
Figure 3. Trypanosoma cruzi metacyclic trypomastigotes on a peripheral blood smear shown by Giemsa staining.
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bug´s midgut to epimastigote forms and multiply by binary fission. Finally, the highly infec-
tious metacyclic trypomastigotes develop in the rectum of the bug, and will be passed again 
with the feces during a subsequent second blood meal [14].
3. Epidemiology
Following a decline in incidence in endemic countries of Latin America, recorded in the mid-
1990s up to the beginning of this millennium due to vector-eradication campaigns, Chagas’ 
disease is currently worldwide on the rise again even in Europe [15–21]. Alternative transmis-
sion modes of Chagas’ disease, such as congenital infection and infection through contaminated 
blood and organ donations, now play a major role both in classical endemic areas and in coun-
tries outside Latin America due to an increase in worldwide migration. The disease is, therefore, 
increasingly being detected in Europe, since more than 14 million people have left the endemic 
areas of South America, four to five million for Europe [22]. In a statement from the WHO for 
Chagas’ disease in Europe in 2010, the number of T. cruzi-infected individuals in Europe is esti-
mated at 80,000–100,000. Switzerland is home to a group of people at risk, and it is estimated 
that of the approximately 40,000 legal immigrants from Latin America, 2000–4000 people may 
have become infected with this pathogen [23]. In Spain, the estimated number of people infected 
with T. cruzi, most of these being legal immigrants from South America, is 25,000–48,000 [17, 18].
Chagas’ disease can also pose a threat to Germany. The data collection among the approxi-
mately 85,000 immigrants coming from endemic areas is, however, incomplete. It is estimated 
Figure 4. Intracytoplasmic localization of T. cruzi amastigotes in cultured fibroblasts stained with Giemsa at low (left) and 
high (right) magnification. Arrows mark intracellular amastigotes, and the arrow head (left) indicates an extracellular 
trypomastigote.
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that the prevalence of seropositive immigrants is 1.3–1.7% (1100–1450-infected individuals); 
however, it is assumed that the number of patients is significantly underdiagnosed with 
Chagas’ disease [18, 24]. Epidemiological data from the United States of America estimated 
up to a million people infected with T. cruzi, and for the entire American continent includ-
ing Mexico up to seven million [25]. In South America, Bolivia is the country with by far the 
highest infection rate, and serological screening in maternity hospitals detected up to 23.6% 
pregnant women infected with the parasite [26]. Recent data also underline the spread with 
increasing prevalence of Chagas’ disease in Australia and New Zealand [27].
4. Symptomatology of Chagas’ disease
Infection with T. cruzi can be divided into three distinct phases: the acute, indeterminate 
(latent), and chronic phase. The acute phase is characterized by the detection of circulating 
trypomastigotes in the blood. The majority of patients infected in adulthood are asymptom-
atic or show only mild and nonspecific symptoms. Children, however, are much more suscep-
tible to a recognizable acute infection with T. cruzi and often have a higher parasitemia than 
adults. After an incubation period of 1–3 weeks, local inflammatory reactions develop at the 
entry point. In about half of all cases, the eye is the primary portal of entry. Parasites penetrate 
transconjunctivally into mesenchymal cells or are phagocytosed by macrophages and cause 
a local inflammatory reaction. Characteristic for acute Chagas’ disease is a periorbital edema 
accompanied by conjunctivitis, which is termed Româna’s sign.
Inflammatory lesions or nodules on the puncture wound in the face are less frequently 
observed manifestations of the acute stage (Chagoma), indicating a local inflammatory 
response with tissue destruction. Invasion of neutrophils and activation of tissue macro-
phages result in the secretion of pro-inflammatory cytokines such as tumor necrosis factor-α 
(TNF-α) and interferon-γ (IFN-γ). After a further 1–2 weeks, the stage of hematogenous 
and lymphatic spread is achieved, and further clinical symptoms of the acute phase may 
develop such as fever, anemia, muscle and bone pain, fatigue, diarrhea, lymphadenopathy, 
and hepatosplenomegaly. Whereas these symptoms typically disappear after 3–4 months, a 
small number of individuals, especially children, die from complications such as myocarditis 
or meningoencephalitis. The fatal course is highly dependent on the immune system and 
nutritional status of the host as well as the parasite load during transmission. The subsequent 
indeterminate phase is characterized by a very low parasitemia in the blood and can last for 
decades. Cellular immunity is at this stage an important endogenous strategy of the host to 
keep the parasites under control. Usually, 20–30% of seropositive patients develop the chronic 
phase of Chagas’ disease [28]. In 40–50% of the affected patients, a progressive cardiomyopa-
thy and less frequently neuronal dysfunction of the autonomic nerves of the gastrointestinal 
tract can develop [29]. These symptoms are often found clinically only at a later stage, as 
many patients are initially asymptomatic. During routine analysis, radiological signs of left 
heart failure and cardiomegaly can be found. Damage to the heart may result in atrioventricu-
lar (AV), His-bundle or intraventricular blocks with Adam-Stokes seizures and syncopes [30]. 
Cellular hypertrophy and subsequent chamber enlargement lead to systolic heart failure and 
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may result in arrhythmias. Patients often die of sudden cardiac death induced by ventricu-
lar tachycardia and congestive heart failure [31]. Histopathologic examination of endomyo-
cardial biopsies shows myocardial fibrosis, resulting from cell lysis by trypanosomes and/
or immune-pathological mechanisms. Development of gastrointestinal mega-syndrome, par-
ticularly the esophagus and colon, are additional clinical manifestations of chronic Chagas’ 
disease. The formation of mega-organs results from the destruction of the parasympathetic 
ganglia of the Meissner and Auerbach plexus in the gastrointestinal tract, which critically 
impairs peristalsis and leads to the ballooning of the organs. Clinically, these patients show 
symptoms of dysphagia, regurgitation, constipation, and secondary achalasia resulting from 
the dysfunction of the lower esophageal sphincter.
5. Diagnosis and treatment
Based on the aforementioned clinical signs of T. cruzi infection, chronic Chagas’ disease is 
diagnosed using conventional methods in clinical cardiology. The electrocardiogram (ECG) is 
the diagnostic tool of choice in the question of Chagas’ cardiomyopathy. Magnetic resonance 
imaging (MRI) allows noninvasive and accurate assessment of inflammatory infiltrates of the 
heart muscle and the identification of an apical ventricular aneurysm. To confirm the diagno-
sis, a series of laboratory tests should be employed. The classic laboratory diagnostic measure 
to confirm an acute infection is a blood smear, which is stained after fixation with Giemsa 
and typically shows motile trypanomastigotes. The serological diagnosis comprises detec-
tion of both immunoglobulin (Ig) M and IgG antibodies against T. cruzi using enzyme-linked 
immunosorbent assay (ELISA), indirect hemagglutination assay (IHA) or indirect immuno-
fluorescence assay (IFA). For suspected Chagas’ disease, the WHO recommends two mutually 
independent tests [32]. The polymerase chain reaction (PCR) for the detection of nucleic acid 
sequences of parasites can be used to detect parasites in organ transplants, as well as to test 
the parasite load during and after chemotherapy. Finally, in unclear serological cases and 
when the blood smear is repeatedly negative, the xenodiagnosis developed by the French par-
asitologist Alexander Joseph Émile Brumpt may be applied using confirmed T. cruzi-negative 
assassin bugs, which take a blood meal on the patient´s skin. After 10–30 days, in the case of 
an infection of the patient with T. cruzi, even at low parasitemia, metacyclic trypomastigotes 
of T. cruzi can be demonstrated in the intestine of the bug and confirm the diagnosis [33].
In principle, two drugs for the treatment of acute Chagas’ disease are available, nifurtimox and 
benznidazole, which require prolonged treatment and may cause significant side effects [34]. 
Nifurtimox, a nitrofuran with antiparasitic activity against both life cycle stages in the host, 
causes the accumulation of free radicals and superoxides and is generally genotoxic [35]. The 
nitroimidazole derivate benznidazole is an antiparasitic medication equally effective against 
the two life-cycle stages. This drug inhibits the synthesis of RNA and generates the accumula-
tion of superoxides [35]. Although the parasite burden can be reduced below the detection 
limit in about 70% of all pharmacologically treated cases in acute Chagas’ disease, there is 
still no evidence that antiparasitic treatment can cure the patient completely from T. cruzi [36–
38]. Data for the treatment of patients with chronic Chagas’ heart disease are not sufficiently 
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 validated to recommend a basic chemotherapy for these patients due to the unfavorable side-
effect profile. In nonrandomized clinical or animal studies, some authors conclude that treat-
ment with benznidazole may also be of benefit during the chronic phase, since thus severe 
courses of Chagas’ cardiomyopathy can be avoided [39, 40]. However, results from the mul-
ticenter, randomized Benznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) 
trial to assess the efficacy and safety of benznidazole treatment in patients with chronic 
Chagas’ cardiomyopathy demonstrated that anti-trypanocidal therapy does not significantly 
reduce clinical deterioration through 5 years of follow-up as compared to placebo, despite 
reductions in the parasite load in serum samples [41]. These findings emphasize the urgent 
need for the development of new pharmacological agents against chronic Chagas’ disease.
6. Prevention
Hitherto, the only sure prevention of the disease is the exposure prophylaxis by aerial spray-
ing of insecticides and by modernization of traditional huts in rural areas. T. cruzi-infected 
pets, especially dogs and cats, provide a large reservoir of pathogens. Some countries perform 
an obligatory blood bank screening for the pathogen of Chagas’ disease. These include, for 
example, Brazil, Uruguay, Argentina, Colombia, and the United States, but also Spain and 
Portugal. A vaccination against T. cruzi does not yet exist. Surface components of the parasite, 
particularly glycolipids such as glycosylphosphatidylinositol (GPI) anchors, have been well 
studied for their role in infectivity [42]. Trypanosomal trans-sialidase, belonging to the family 
of GPI-anchored proteins which transfer sialic acids from the cell membrane of the host to 
glycoproteins on the parasite surface, is involved in the infection of the host cell, and trans-
sialidase inhibitors have been successfully tested in vitro [43].
7. Innate immune response to infections with T. cruzi
The innate immune system is essential in order to control the spread of T. cruzi parasites in 
the body and to ensure the survival of the host [44]. Pattern recognition receptors (PRRs), 
particularly the transmembrane toll-like receptors (TLRs), recognize the so-called pathogen-
associated molecular patterns (PAMPs) in microorganisms [45]. Binding of glycoinositol-
phospholipids (GIPL), GPI anchors, DNA, and RNA fragments of T. cruzi to TLR2, TLR4, 
TLR7, and TLR9 initiates a signaling cascade that finally activates important pro-inflamma-
tory processes [46–52]. In myocarditis, genes for the endogenous TLR-7 and TLR-9 recep-
tors are upregulated and their gene products serve as potential biomarkers for inflammatory 
heart disease [53]. Through the adapter molecule myeloid differentiation factor 88 (MyD88), a 
signal pathway is activated that finally leads to the upregulation of pro-inflammatory genes, 
such as interleukin-(IL)-1β [54], IL-6 [55], IL-12 [56–60], TNF-α [57, 58, 61], IFN-β [62–64], and 
IFN-γ [54, 59–61, 65–67].
Activation of these pathways is critical for resistance to infection with T. cruzi. Mice function-
ally deficient in MyD88 expression are more susceptible to infection by this protozoan, which 
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is probably due to a defect in the production of pro-inflammatory cytokines [68]. In T. cruzi-
infected macrophages, the expression of pro-inflammatory cytokines is mediated by two tran-
scription factors: nuclear factor-κB (NF-κB) [69–71] and interferon-regulatory factor 3 (IRF3) 
[64]. NF-kB also activates inducible NO synthase (iNOS) which catalyzes the production of 
microbicidal nitric oxide (NO). Mice with a deficiency of iNOS or IFN-γ receptor are sensitive 
to infection with T. cruzi, showing a high rate of parasitemia, and, furthermore, macrophages 
from these mice have impaired trypanocidal activity due to lower amounts of NO [72].
8. Apoptosis of cardiac myocytes in Chagas’ disease
The chronic stage of Chagas’ disease usually leads to symptoms of dilated cardiomyopathy, 
which is characterized by an enlargement of the heart muscle with a steadily progressive loss 
of systolic function. The decrease in the biventricular ejection volume is presumably reflecting 
altered heart muscle remodeling and may include apoptotic cell death. Apoptosis is a form of 
programmed cell death which differs from necrosis by actively carrying out a cell-death pro-
gram [73]. Apoptosis-regulating genes such as Bax and Apaf-1 are involved in the execution 
of apoptosis, whereas Bcl-2 is an antiapoptotic protein.
Proteolytic enzymes termed caspases play a central role in the execution of apoptotic cell 
death. The activation of the caspase cascade can be initiated by both intra- and extracellular 
stimuli. Extracellular stimuli induce the activation of caspases 8 and 10 through the Fas ligand 
and TNF receptors, whereas the intracellular pathway consists of the cytochrome C-regulated 
apoptosome which activates caspase 9. The JAK-STAT-signaling pathway regulates apoptosis 
via STAT3 (signal transducer and activator of transcription 3) by promoting the expression of 
antiapoptotic genes coding for the Bcl-2 protein family [74]. Cytotoxic T lymphocytes (CTLs, 
CD8+ T-cells) activate caspases 3 and 7. These are key caspases in which caspases 8 and 9 con-
verge and henceforth result in a common final pathway of the signaling cascade. Apoptosis 
of cardiomyocytes in the context of T. cruzi infection is a potential mechanism of the host to 
limit the spread of parasites.
In autopsy samples from Chagas’ cardiomyopathy patients, signs of apoptotic cell death were 
detected post mortem in cardiac myocytes [75], confirming earlier results that T. cruzi-infected 
cardiomyocytes undergo fibrosis and apoptotic cell death [76, 77]. Zhang and colleagues 
detected apoptosis in a canine model of acute chagasic myocarditis characterized by the pres-
ence of amastigotes and trypomastigotes of T. cruzi within the cytoplasm of cardiac muscle 
cells [76]. In a gene expression study, Manque and colleagues showed that the infection of 
murine cardiomyocytes with T. cruzi resulted in the upregulation of the two classical pro-
apoptotic genes bid, encoding BH3-interacting domain death agonist, and fas which encodes a 
member of the TNF receptor gene. In addition, the gadd45b gene engaged in cell cycle control, 
DNA repair, and apoptosis was upregulated upon infection [78].
However, there are conflicting results on the role of apoptosis in murine cardiomyocytes 
during infection with T. cruzi trypomastigotes. De Souza et al. reported that cardiomyocytes 
became apoptotic after infection with different strains of T. cruzi [79], whereas Aoki et al. 
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showed that the cysteine protease cruzipain on the surface of T. cruzi appears to have a pro-
tective effect on the host cell and serves as a survival factor supporting the propagation of the 
parasites [80]. Our group demonstrated apoptotic rat cardiomyocytes upon infection with 
either trypomastigote or amastigote stages of T. cruzi [81]. Petersen et al. showed that both 
T. cruzi infection and activation of NF-κB prevented apoptotic cell death in isolated neonatal 
rat cardiomyocytes [82]. Another study reported that amastigotes presented higher rates of 
apoptosis-like cell death as compared to trypomastigotes [83].
The JAK-STAT-signaling pathway has an important role in cardiomyopathy, myocarditis, 
and myocardial infarction [84]. Cardiomyocytes express various receptors for cytokines and 
growth factors (among others, TNFα and EGF) on their surface. Secreted cytokines or growth 
factors may be involved in the apoptotic cell death of cardiomyocytes and chronic cardiomy-
opathy. Specifically, the balance in the activation state of the two related transcription factors 
STAT1 and STAT3 may determine the outcome between cell death and survival of cardiac 
muscle cells during infection with T. cruzi [85].
In the context of chronic Chagas’ disease, which can develop up to 25 years after parasitic 
infection, the question arises as to how the parasite can persist and replicate for such a long 
period of time in the host without causing an exacerbating immune response. The most obvi-
ous explanation is that the parasite has developed effective mechanisms to circumvent the 
immune response which affects the steady balance between parasite load and apoptosis-
induced destruction of host cells. Various parasitological studies highlight the dogma that the 
replication of parasites in the cardiac myocytes is required to initiate the complete picture of 
Chagas’ heart disease ranging from acute myocarditis to chronic cardiomyopathy [86].
9. The role of STAT proteins in Chagas’ cardiomyopathy
There is growing evidence that not only NF-kB but also STAT transcription factors are engaged 
in T. cruzi infection. Recently, we have demonstrated that serine phosphorylation of STAT1 at 
position 727 is targeted by T. cruzi, suggesting that the parasite inhibits the antiparasitic effects 
of STAT1 [87] (Figure 5). Ponce and coworkers reported that the secretion of endogenous IL-6 
or the addition of recombinant IL-6 protects cardiomyocytes from cell death by apoptosis 
during an infection with T. cruzi [88]. Furthermore, the authors showed the phosphorylation 
of STAT3 at tyrosine 705 by IL-6 in response to infection with T. cruzi. In cardiac tissues, the 
expression of the STAT3-regulated antiapoptotic factor Bcl-2 was increased, suggesting that, 
during the acute phase of infection with T. cruzi, tyrosine-phosphorylated STAT3 acts as a 
mediator of cell survival. In summary, the results of this important study suggest that STAT3 
executes pro-survival effects in cardiac muscle cells evoked by the parasite.
In addition, Ponce et al. demonstrated that, in T. cruzi-infected cells, the release of IL-6 via a 
TLR2-dependent pathway is required to induce survival of cardiomyocytes [88]. The enzy-
matic activity of cruzipain, the main cysteine protease secreted by this parasite, critically 
interferes with IL-6-mediated STAT3 phosphorylation by means of cleavage of the ectodo-
main of glycoprotein gp130, which is the shared receptor of several IL-6-type cytokines [89]. 
The parasite cysteine protease inhibitor chagasin inhibits cruzipain-induced gp130 cleavage, 
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suggesting that the pro-inflammatory IL-6 response in T. cruzi-infected cells is modified by 
cysteine protease activity. In addition, it has been well established that STAT transcription 
factors activate genes whose products have been identified as suppressors of cytokine signal-
ing (SOCS) which act as inhibitors of the JAK-STAT pathway in a negative feedback loop [90].
Previous studies have described how STAT3 is activated by the two cytokines IL-6 or IL-10 
[91, 92] and how the expression of SOCS3 is upregulated by the anti-inflammatory IL-10 in T. 
cruzi-infected cardiomyocytes [71]. During chronic infection with T. cruzi, the expression of 
SOCS2 is upregulated and most probably plays a significant role in the etiopathogenesis of 
Chagas’ heart disease by influencing heart muscle damage [93].
Another member of the STAT family, the transcription factor STAT4, is activated in response 
to the cytokine IL-12, which acts as a pro-inflammatory cytokine and drives Th cells along a 
Th1 lineage. STAT6 is activated by receptor binding of two cytokines with anti-inflammatory 
properties, IL-4 and IL-13, which provide an alternative signal for the development along a 
Th2 lineage. Tarleton and coworkers demonstrated that STAT4-deficient mice were highly 
susceptible to infection with T. cruzi, whereas STAT6-deficient mice showed enhanced resis-
tance with lower parasitemia and little or no evidence of inflammatory processes in the heart 
muscle as compared to their wild-type littermates [94]. The apparent absence of disease in 
chronically infected STAT6-deficient mice is remarkable despite their inability to achieve entire 
parasite clearance. The findings in this investigation suggest that the severity of inflammation 
critically depends on STAT4- and STAT6-mediated cytokine-driven immune reactions which 
modulate tissue parasite load [94]. Finally, the authors infer that the clearance of intracellular 
parasites may not be required to prevent the progression of the disease to cardiomyopathy.
10. Concluding remarks
In summary, the pathogenic protozoan T. cruzi has evolved complex and still undefined 
mechanisms to circumvent an effective immune response in the human myocardium. The 
Figure 5. Illustration of a cardiac myocyte showing replicating intracellular T. cruzi parasites that evade the protective 
role of IFN-γ signaling by targeting essential components of the JAK-STAT pathway such as the dephosphorylation 
of STAT1 at serine 727. While phosphorylation of STAT1 serine 727 is required for full transcriptional activity, its 
dephosphorylation inhibits antiparasitic effects of STAT1.
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bypassing of protective signaling pathways by the parasite such as the JAK-STAT pathway may 
account for the intracellular multiplication and long-lasting persistence of T. cruzi in the host. 
Amastigotes of T. cruzi proliferating in the cytoplasm of infected cardiomyocytes have devel-
oped effective strategies to counteract the attack executed by STAT proteins, which are crucial 
for an effective immune defense against the protozoan. Further research efforts are required to 
elucidate the role of cytokine-driven gene expression in the fight against the parasite.
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